Table 2.

Subgroup analyses of overall survival (OS) and progression-free survival (PFS)

Outcome	Subgroups	No. of studies	Effects model	HR (95% CI)	p	Heterogeneity
						I2 (%)	p
OS	All	10	Random	1.44 (1.23, 1.69)	0.001	88.0	0.001
Ethnicity	Asian	3	Random	2.18 (1.19, 4.00)	0.012	65.3	0.056
	Nonasian	6	Random	1.26 (1.08, 1.46)	0.002	89.5	0.000
Tumor type	CRPC	8	Random	1.37 (1.17, 1.60)	0.000	89.3	0.000
	mPCa	7	Random	1.75 (1.17, 2.60)	0.006	90.4	0.000
Treatment	Radiotherapy	2	Random	1.55 (0.67, 3.58)	0.308	97.3	0.000
	Chemotherapy	5	Random	1.39 (1.00, 1.93)	0.052	72.0	0.006
	Chemotherapy + ARTA	3	Random	1.94 (1.03, 3.67)	0.041	69.3	0.038
Sample size	≤ 200	7	Random	1.09 (0.98, 1.22)	0.098	71.5	0.002
	> 200	3	Random	2.54 (1.55, 4.16)	0.000	70.1	0.035
Cut off value	≤ 580	5	Random	1.61 (1.07, 2.43)	0.022	84.9	0.000
	> 580	5	Random	1.85 (1.07, 3.19)	0.028	82.4	0.000
PFS	All	6	Random	1.80 (1.27, 2.56)	0.001	92.0	0.000
Ethnicity	Asian	3	Random	4.03 (1.07, 15.17)	0.039	93.2	0.000
Tumor type	CRPC	3	Random	2.30 (0.88, 6.00)	0.089	95.5	0.000
	nmPCa	3	Random	1.78 (0.94, 3.35)	0.075	86.3	0.001
Treatment	Chemotherapy	2	Random	1.31 (0.71, 2.41)	0.389	84.9	0.010
	Chemotherapy + ARTA	2	Random	3.04 (0.22, 42.53)	0.408	96.7	0.000
	RP	3	Random	1.78 (0.94, 3.35)	0.075	86.3	0.001
Sample size	≤ 200	3	Random	2.30 (0.88, 6.00)	0.089	95.5	0.000
	> 200	3	Random	1.78 (0.94, 3.35)	0.075	86.3	0.001
Cut off value	≤ 580	3	Random	3.65 (0.72, 18.37)	0.116	96.7	0.000
	> 580	3	Random	1.19 (1.04, 1.36)	0.010	0.0	0.599

HR hazard ratio, CI confidence interval, OS overall survival, PFS progression-free survival, CRPC castration-resistant prostate cancer, mPCa metastatic prostate cancer, nmPCa nonmetastatic prostate cancer, ARTA androgen receptor targeting agents, RP radical prostatectomy